Literature DB >> 15648243

Foreign particles testing in orally inhaled and nasal drug products.

James Blanchard, James Coleman, Claire D'Abreu Hayling, Raouf Ghaderi, Barbara Haeberlin, John Hart, Steen Jensen, Richard Malcolmson, Stanley Mittelman, Lee M Nagao, Sonja Sekulic, Caesar Snodgrass-Pilla, Mikael Sundahl, Glenn Thompson, Ronald Wolff.   

Abstract

The International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS) presents this paper in order to contribute to public discussion regarding best approaches to foreign particles testing in orally inhaled and nasal drug products (OINDPs) and to help facilitate development of consensus views on this subject. We performed a comprehensive review of industry experience and best practices regarding foreign particles testing in OINDPs, reviewed current guidances and techniques, and considered health and safety perspectives. We also conducted and assessed results of an industry survey on U.S. Food and Drug Administration requirements for foreign particles testing. We provide here a result of our review and survey: a summary of industry best practices for testing and controlling foreign particles in OINDPs and proposals for developmental characterization and quality control strategies for foreign particles. We believe that clear consensus-based recommendations and standards for foreign particles testing and control in OINDPs are needed. The proposals contained in this paper could provide a starting point for developing such consensus recommendations and standards.

Mesh:

Substances:

Year:  2004        PMID: 15648243     DOI: 10.1007/s11095-004-7665-7

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  13 in total

Review 1.  Pulmonary effects of inhaled ultrafine particles.

Authors:  G Oberdörster
Journal:  Int Arch Occup Environ Health       Date:  2001-01       Impact factor: 3.015

2.  Does lung retention of inhaled particles depend on their geometric diameter?

Authors:  K Philipson; R Falk; M Svartengren; N Jarvis; M Bailey; R Bergmann; W Hofmann; P Camner
Journal:  Exp Lung Res       Date:  2000-09       Impact factor: 2.459

3.  Ultrafine particles in human lung macrophages.

Authors:  R Hauser; J J Godleski; V Hatch; D C Christiani
Journal:  Arch Environ Health       Date:  2001 Mar-Apr

4.  Pulmonary retention of ultrafine and fine particles in rats.

Authors:  J Ferin; G Oberdörster; D P Penney
Journal:  Am J Respir Cell Mol Biol       Date:  1992-05       Impact factor: 6.914

5.  Size-dependent proinflammatory effects of ultrafine polystyrene particles: a role for surface area and oxidative stress in the enhanced activity of ultrafines.

Authors:  D M Brown; M R Wilson; W MacNee; V Stone; K Donaldson
Journal:  Toxicol Appl Pharmacol       Date:  2001-09-15       Impact factor: 4.219

6.  An association between air pollution and mortality in six U.S. cities.

Authors:  D W Dockery; C A Pope; X Xu; J D Spengler; J H Ware; M E Fay; B G Ferris; F E Speizer
Journal:  N Engl J Med       Date:  1993-12-09       Impact factor: 91.245

7.  Particulate air pollution as a predictor of mortality in a prospective study of U.S. adults.

Authors:  C A Pope; M J Thun; M M Namboodiri; D W Dockery; J S Evans; F E Speizer; C W Heath
Journal:  Am J Respir Crit Care Med       Date:  1995-03       Impact factor: 21.405

8.  Influence of particle surface area on the toxicity of insoluble manganese dioxide dusts.

Authors:  D Lison; C Lardot; F Huaux; G Zanetti; B Fubini
Journal:  Arch Toxicol       Date:  1997       Impact factor: 5.153

9.  Breathing patterns. 2. Diseased subjects.

Authors:  M J Tobin; T S Chadha; G Jenouri; S J Birch; H B Gazeroglu; M A Sackner
Journal:  Chest       Date:  1983-09       Impact factor: 9.410

10.  Correlation between particle size, in vivo particle persistence, and lung injury.

Authors:  G Oberdörster; J Ferin; B E Lehnert
Journal:  Environ Health Perspect       Date:  1994-10       Impact factor: 9.031

View more
  3 in total

1.  Best practices for managing quality and safety of foreign particles in orally inhaled and nasal drug products, and an evaluation of clinical relevance.

Authors:  James Blanchard; James Coleman; Courtney Crim; Claire Dabreu-Hayling; Lou Fries; Raouf Ghaderi; Barbara Haeberlin; Richard Malcolmson; Stanley Mittelman; Lee Nagao; Ilie Saracovan; Liuda Shtohryn; Caesar Snodgrass-Pilla; Mikael Sundahl; Ronald Wolff
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

Review 2.  Nanotechnology: intelligent design to treat complex disease.

Authors:  Patrick Couvreur; Christine Vauthier
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.580

Review 3.  Inhaled antibodies: Quality and performance considerations.

Authors:  Anthony James Hickey; Ian Edward Stewart
Journal:  Hum Vaccin Immunother       Date:  2021-06-30       Impact factor: 4.526

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.